C-List and Commercial Catalog Masterclass Strategy Panel
Industry leaders unpack China’s evolving multi-level coverage system—what the dual-list means for pricing risk, NRDL vs. commercial access, and long-term strategy in the C-List era.
Not yet a member?
Access360 membership provides structured intelligence on China’s evolving health policy, coverage, and financing system, with member briefings, archive access, and opportunities to submit questions on published analyses.
Explore Membership